U.S. patent application number 10/541785 was filed with the patent office on 2006-08-17 for filter for removing fibrinogen, filter device for removing fibrinogen, and method of removing fibrinogen using the same.
Invention is credited to Hironobu Isogawa, Yoshinori Uji.
Application Number | 20060182663 10/541785 |
Document ID | / |
Family ID | 32775173 |
Filed Date | 2006-08-17 |
United States Patent
Application |
20060182663 |
Kind Code |
A1 |
Uji; Yoshinori ; et
al. |
August 17, 2006 |
Filter for removing fibrinogen, filter device for removing
fibrinogen, and method of removing fibrinogen using the same
Abstract
It is intended to provide a filter for removing fibrinogen and a
filter device for removing fibrinogen and a method of removing
fibrinogen using the same by which a serum sample not affecting
blood examination data can be quickly prepared from plasma. A
filter for removing fibrinogen from plasma which is made of a fiber
mass, microparticles or a porous polymer capable of adsorbing
fibrinogen, has a surface area of 0.5 m.sup.2/g or larger and a
porosity of 85% or lower.
Inventors: |
Uji; Yoshinori; (Yamaguchi,
JP) ; Isogawa; Hironobu; (Tokyo, JP) |
Correspondence
Address: |
TOWNSEND & BANTA;c/o PORTFOLIO IP
PO BOX 52050
MINNEAPOLIS
MN
55402
US
|
Family ID: |
32775173 |
Appl. No.: |
10/541785 |
Filed: |
January 21, 2004 |
PCT Filed: |
January 21, 2004 |
PCT NO: |
PCT/JP04/00480 |
371 Date: |
July 11, 2005 |
Current U.S.
Class: |
422/400 |
Current CPC
Class: |
B01J 20/262 20130101;
B01J 2220/66 20130101; B01J 20/26 20130101; B01J 2220/64 20130101;
B01J 20/28023 20130101; B01J 20/28057 20130101; B01J 20/28095
20130101; B01J 20/28069 20130101 |
Class at
Publication: |
422/101 |
International
Class: |
B01L 3/00 20060101
B01L003/00 |
Foreign Application Data
Date |
Code |
Application Number |
Jan 22, 2003 |
JP |
2003-013754 |
Jan 4, 2003 |
JP |
2003-108163 |
Claims
1. A filter for removing fibrinogen from plasma, which comprises a
fiber mass, microparticles or a porous polymer capable of adsorbing
fibrinogen, the filter having a surface area of 0.5 m.sup.2/g or
larger and a porosity of 85% or lower.
2. The filter for removing fibrinogen according to claim 1, which
adsorbs fibrinogen in an amount of 1 mg or more per g of the
filter.
3. The filter for removing fibrinogen according to claim 1 or 2,
wherein the fiber mass, microparticles or porous polymer capable of
adsorbing fibrinogen comprises polyester-based resin.
4. A method of removing fibrinogen from plasma, which comprises
using the filter for removing fibrinogen according to claim 1, 2 or
3 to remove fibrinogen from plasma.
5. A filter device for removing fibrinogen from plasma, which
comprises a tubular container charged with a fiber mass,
microparticles or a porous polymer capable of adsorbing
fibrinogen.
6. A method of removing fibrinogen, which comprises injecting
plasma into the container of the filter device for removing
fibrinogen according to claim 5 and then pressurizing it at a
plasma injection side or suctioning it at a filtered-plasma outlet
side, thereby passing plasma through a fiber mass, microparticles
or a porous polymer capable of adsorbing fibrinogen.
7. A method of removing fibrinogen, wherein in the tubular
container of the filter device for removing fibrinogen according to
claim 5, which is provided with a piston contacting liquid-tightly
with an internal peripheral wall of the tubular container and
capable of moving in the lengthwise direction of the tubular
container, and is provided, in the tubular container, with a plasma
suctioning opening in an opposite side to the side where the piston
for the fiber mass, microparticles or porous polymer is arranged,
the piston is transferred in such a direction as to become more
distant from the plasma suctioning opening while the plasma
suctioning opening is dipped in plasma, thus suctioning the plasma
into the tubular container and passing the plasma through the fiber
mass, microparticles or porous polymer.
Description
TECHNICAL FIELD
[0001] The present invention relates to a method of removing
fibrinogen contained in serum or plasma and a member therefore.
BACKGROUND ART
[0002] Blood examinations are widely used in order to diagnose
diseases in laboratory tests. Many blood examinations are serum
examinations, and serum required in these examinations is usually
separated from a clot having different specific gravity (that is, a
gel-like mass containing a mixture of fibrin and blood-cell
components) by coagulating blood collected in a blood examination
container and then centrifuging it. A coagulation-promoting
component is added to the blood examination container in order to
coagulate blood, and as the coagulation-promoting component, an
adsorptive inorganic material has been conventionally used, but
recently an enzyme such as thrombin and venom is used to reduce the
coagulation time thus reducing the time necessary for obtaining
examination results thereby improving convenience.
[0003] On one hand, an anti-coagulant is administered into blood of
patients undergoing dialysis who are increasing year by year, thus
making the coagulation time extraordinarily long and significantly
prolonging the time for preparing their samples. For this problem,
a blood coagulation-promoting agent wherein a component
neutralizing heparin as an anti-coagulant is used in combination
with a coagulation-promoting component has been developed and
contributed to reduction in coagulation time (see JP-A No.
62-240617 and JP-A No. 63-275953).
[0004] However, even if coagulation is completed by using the blood
coagulation-promoting agent to lose the fluidity of blood, fibrin
can be precipitated gradually in serum after centrifugation, and a
nozzle of an examination device is often clogged with the
fibrin.
[0005] Accordingly, a method of obtaining serum by removing
fibrinogen contained in plasma by using a high-molecular fiber mass
rendered hydrophilic has been developed as described in JP-A No.
2000-309539.
[0006] In the method described in JP-A No. 2000-309539 supra,
however, protein such as albumin contained in plasma may also be
simultaneously removed by adsorption, and thus there is a problem
that a sample obtained by this method cannot be subjected to blood
examination where such substance is a subject of examination.
DISCLOSURE OF THE INVENTION
[0007] In view of the circumstances described above, the object of
the present invention is to provide a filter for removing
fibrinogen and a filter device for removing fibrinogen, by which a
serum sample not affecting results of blood examination can be
rapidly prepared from plasma, and a method of removing fibrinogen
by using the same.
[0008] A first aspect of the present invention is concerned with a
filter for removing fibrinogen from plasma, which comprises a fiber
mass, microparticles or a porous polymer capable of adsorbing
fibrinogen, and has a surface area of 0.5 m.sup.2/g or larger and a
porosity of 85% or lower.
[0009] A second aspect of the present invention is concerned with a
filter device for removing fibrinogen from plasma, which comprises
a cylindrical container charged with a fiber mass, microparticles
or a porous polymer capable of adsorbing fibrinogen.
[0010] Hereinafter, the present invention is described in more
detail.
[0011] The filter for removing fibrinogen in the first aspect of
the invention is to remove fibrinogen from plasma.
[0012] The plasma is obtained usually by centrifuging
anti-coagulant-containing blood to precipitate blood cells, and
recovering the resulting transparent, pale yellow supernatant.
[0013] In the present invention, the plasma includes serum
containing fibrinogen mixed therein.
[0014] The filter for removing fibrinogen in the first aspect of
the present invention comprises a fiber mass, microparticles or a
porous polymer capable of adsorbing fibrinogen.
[0015] The fiber mass, microparticles or porous polymer capable of
adsorbing fibrinogen is not particularly limited and may be made of
any material insofar as it is capable of adsorbing fibrinogen.
However, the filter for removing fibrinogen in the first aspect of
the invention is used in blood examination, and should thus not
contain metal salts such as those of iron, zinc, magnesium,
aluminum etc. or sodium ion, potassium ion, chloride ion etc. in
such an amount as to affect the examination. This also applies to
organic matter etc.
[0016] The fiber mass, microparticles or porous polymer capable of
adsorbing fibrinogen is made of, for example, polyester-based resin
such as polyethylene terephthalate, polybutylene terephthalate
etc., nylon resin, polyurethane resin, polystyrene-based resin,
homo- or copolymer resin of poly(meth)acrylates such as polymethyl
methacrylate, and copolymer resin of polyethylene and vinyl acetate
or (meth)acrylates. These may be used singly or as a mixture of two
or more thereof. The filter composed of the polyester-based resin
among these resins is preferably used from the viewpoint of the
balance between the performance of adsorbing fibrinogen and the
influence of the filter on measurements of samples after
treatment.
[0017] Generally a material adsorbing fibrinogen is liable to
adsorb other hydrophobic proteins. Accordingly, the surface of the
filter made of the fiber mass, microparticles or porous polymer
capable of adsorbing fibrinogen should be subjected to
hydrophilization treatment depending on the case, in order to
control surface properties. The hydrophilizating agent is not
particularly limited, and includes, for example, hydrophilic
synthetic polymers and naturally occurring water-soluble polymers
such as polyvinyl alcohol, polyvinyl pyrrolidone etc. and polymer
surfactants such as polyether-modified silicone etc.
[0018] The filter for removing fibrinogen in the first aspect of
the invention has a surface area of 0.5 m.sup.2/g or larger and a
porosity of 85% or lower.
[0019] As the surface area of the filter is increased, the
efficiency of removal of fibrinogen is improved, while as the
surface area is less than 0.5 m.sup.2/g, more filters are necessary
to remove fibrinogen, thus increasing costs. When the porosity is
higher than 85%, the yield of plasma is reduced. Preferably, the
surface area is 0.7 m.sup.2/g or larger and the porosity is 80% or
lower.
[0020] The surface area of the filter for removing fibrinogen is
determined from average fiber diameter, fiber weight, and density
by the following formula (1): Surface area=(4.times.fiber
weight)/(material density.times.average fiber diameter) (1)
[0021] The porosity is determined from filter material density,
weight, and volume after compression by the following formula (2):
Porosity={1-weight/(material density.times.volume after
compression)}.times.100 (2)
[0022] The filter for removing fibrinogen in the first aspect of
the invention is preferably the one adsorbing 1 mg or more
fibrinogen per g of the filter. When the amount of fibrinogen
adsorbed per g of the filter is less than 1 mg, more filters are
necessary for attaining necessary performance of adsorbing
fibrinogen, which may result in a reduction in the amount of plasma
recovered.
[0023] Using the filter for removing fibrinogen in the first aspect
of the invention, fibrinogen can be removed from plasma. The method
of removing fibrinogen by using the filter for removing fibrinogen
in the first aspect of the invention also constitutes one aspect of
the invention.
[0024] The filter device for removing fibrinogen in the second
aspect of the invention is to remove fibrinogen from plasma.
[0025] The filter device for removing fibrinogen in the second
aspect of the invention has a structure wherein a fiber mass,
microparticles or a porous polymer capable of adsorbing fibrinogen
is charged in a tubular container. The tubular container has an
opening in the top and bottom respectively, in which the fiber
mass, microparticles or porous polymer capable of adsorbing
fibrinogen is charged and fixed.
[0026] The tubular container preferably has a cylindrical shape,
but may have another cylindrical shape such as prism. For fixing
the fiber mass, microparticles or porous polymer capable of
adsorbing fibrinogen, the diameter of an opening at the bottom of
the container may be small-sized and a fixing partition plate, an
ancillary material etc. may be inserted into the container.
[0027] The fiber mass, microparticles and porous polymer capable of
adsorbing fibrinogen are the same as in the filter for removing
fibrinogen in the first aspect of the invention.
[0028] For removing fibrinogen from plasma by using the filter
device for removing fibrinogen in the second aspect of the
invention, plasma is first injected into a tubular container of the
filter device for removing fibrinogen in the second aspect of the
invention, and then pressurized from the plasma injection side or
suctioned from the filtered-plasma outlet side, thereby passing
plasma through the fiber mass, microparticles or porous polymer
capable of adsorbing fibrinogen.
[0029] The pressurizing method is not particularly limited, and for
example, a method of using a piston as shown in FIG. 1 can be
mentioned. The suctioning method is not particularly limited, and
for example, a method that involves inserting the filtered-plasma
outlet side of the device into a tube depressurized therein, as
shown in FIG. 2, can be mentioned.
[0030] In the filter device shown in FIG. 1, a fibrinogen adsorbent
2 consisting of a fiber mass, microparticles or a porous polymer
capable of adsorbing fibrinogen is accommodated in a cylindrical
container 1. The fibrinogen adsorbent 2 is preferably composed of
the filter for removing fibrinogen in the first aspect of the
invention. A piston 3 moving while contacting liquid-tightly with
an internal wall of the cylindrical container 1 is accommodated in
the cylindrical container 1. The piston 3 is connected to a piston
rod 3a.
[0031] In the filter device shown in FIG. 2, a fibrinogen adsorbent
2 consisting of a fiber mass, microparticles or a porous polymer
capable of adsorbing fibrinogen is accommodated in a similarly
constituted cylindrical container 1. The fibrinogen adsorbent 2 is
preferably composed of the filter for removing fibrinogen in the
first aspect of the present invention. An injection needle 5 is
attached to the top of the cylindrical container 1. The injection
needle 5 is allowed to pierce through the main body of a vacuum
blood collection tube 4 into the inside of the vacuum blood
collection tube 4. Accordingly, plasma poured into the cylindrical
container 1 is introduced through the fibrinogen adsorbent 2 into
the vacuum blood collection tube 4.
[0032] Another example of the method of removing fibrinogen from
plasma by using the filter device for removing fibrinogen in the
second aspect of the invention is that in a structure comprising a
tubular (preferably cylindrical) container charged with a
fibrinogen adsorbent made of a fiber mass, microparticles or a
porous polymer capable of adsorbing fibrinogen, which is further
provided with a piston capable of moving while contacting
liquid-tightly with an internal surface of the tubular container
and is provided in the tubular container with a plasma suctioning
opening in the opposite side to the piston of the fibrinogen
adsorbent, the piston is transferred to become more distant from
the plasma suctioning opening to suction plasma into the tubular
container, thereby passing the plasma through the fiber mass,
microparticles or porous polymer, resulting in removing fibrinogen.
In this method, bubbles are hardly generated in the collected
plasma.
[0033] An example of the structure of the filter device for
removing fibrinogen used in the method of removing fibrinogen
wherein bubbles are hardly generated as described above is shown in
FIG. 3. In the structure shown in FIG. 3, the fibrinogen adsorbent
2 is accommodated in the cylindrical member 1. The fibrinogen
adsorbent 2 is composed of a fiber mass, microparticles or a porous
polymer, and is preferably constituted according to the first
aspect of the invention. Piston 3 is arranged in an upper part of
the fibrinogen adsorbent 2. The outer periphery of piston 3 is
contacted liquid-tightly with the internal periphery of the
cylindrical member 1. By operating a piston rod 39 connected to an
upper part of piston 3, the piston 3 can move in the cylindrical
member 1 in the lengthwise direction of the cylindrical member 1.
On the other hand, a plasma suctioning opening 1a is arranged below
the fibrinogen adsorbent 2, that is, in the opposite side to the
side of the fibrinogen adsorbent 2 on which piston 3 is arranged.
In this filter device, while the plasma suction opening 1a is
dipped in plasma, piston 3 is transferred upwards, that is, piston
3 is transferred to become more distant from the plasma suctioning
opening 1a, thus introducing the plasma by suction into the
cylindrical member 1. In this case, the plasma is filtered through
the fibrinogen adsorbent 2 to remove fibrinogen.
[0034] As described above, the method of removing fibrinogen from
plasma by using the filter device for removing fibrinogen in the
second aspect of the invention also constitutes one aspect of the
invention.
BRIEF DESCRIPTION OF THE DRAWINGS
[0035] FIG. 1 is a view showing a method wherein the filter device
for removing fibrinogen is pressurized in the plasma injection side
by using a piston.
[0036] FIG. 2 is a view showing a method wherein the filter device
for removing fibrinogen is suctioned in the filtered-plasma outlet
side by using a tube depressurized inside.
[0037] FIG. 3 is a schematic front view for explaining a method
wherein plasma is filtered by suction with a piston arranged in a
cylindrical member having a fibrinogen adsorbent arranged
therein.
BEST MODE FOR CARRYING OUT THE INVENTION
[0038] Hereinafter, the present invention is described in more
detail by reference to the Examples, but the present invention is
not limited to these examples.
Example 1
[0039] A plurality of nonwoven cloths made of polyethylene
terephthalate having an average fiber diameter of 1.8 .mu.m (pile
density 40 g/m.sup.2), each cloth being punched out in a diameter
of 15 mm, were stacked, and 1.0 g specimen was weighed out
therefrom. This specimen was charged into a 10-mL syringe
manufactured by JMS and then pressurized so as to be compressed to
a volume of 4 mL.
Example 2
[0040] A plurality of nonwoven cloths made of polyethylene
terephthalate having an average fiber diameter of 1.8 .mu.m (pile
density 40 g/m.sup.2), each cloth being punched out in a diameter
of 15 mm, were stacked, and 1.0 g specimen was weighed out
therefrom. This specimen was charged into a 10-mL syringe
manufactured by JMS and then pressurized so as to be compressed to
a volume of 3.2 mL.
Example 3
[0041] A plurality of nonwoven cloths made of polyethylene
terephthalate having an average fiber diameter of 1.8 .mu.m (pile
density 40 g/m.sup.2), each cloth being punched out in a diameter
of 15 mm, were stacked, and 1.0 g specimen was weighed out
therefrom. This specimen was charged into a 10-mL syringe
manufactured by JMS and then pressurized so as to be compressed to
a volume of 2.4 mL.
Example 4
[0042] A plurality of nonwoven cloths made of polyethylene
terephthalate having an average fiber diameter of 3.5 .mu.m (pile
density 40 g/m.sup.2), each cloth being punched out in a diameter
of 15 mm, were stacked, and 1.0 g specimen was weighed out
therefrom. This specimen was charged into a 10-mL syringe
manufactured by JMS and then pressurized so as to be compressed to
a volume of 4 mL.
Example 5
[0043] A plurality of nonwoven cloths made of acryl/polyester
(70%/30%) having an average fiber diameter of 3.5 .mu.m (trade
name: Shaleria C1040 (manufactured by Asahi Kasei Corp.), pile
density 40 g/m.sup.2), each cloth being punched out in a diameter
of 15 mm, were stacked, and 1.0 g specimen was weighed out
therefrom. This specimen was charged into a 10-mL syringe
manufactured by JMS and then pressurized so as to be compressed to
a volume of 2 mL.
Example 6
[0044] A plurality of nonwoven cloths made of acryl/rayon (65%/35%)
having an average fiber diameter of 3.5 .mu.m (trade name: Shaleria
CR040 (manufactured by Asahi Kasei Corp.), pile density 40
g/m.sup.2), each cloth being punched out in a diameter of 15 mm,
were stacked, and 1.0 g specimen was weighed out therefrom. This
specimen was charged into a 10-mL syringe manufactured by JMS and
then pressurized so as to be compressed to a volume of 2 mL.
Comparative Example 1
[0045] A plurality of nonwoven cloths made of polyethylene
terephthalate having an average fiber diameter of 1.8 .mu.m (pile
density 40 g/m.sup.2), each cloth being punched out in a diameter
of 15 mm, were stacked, and 1.0 g specimen was weighed out
therefrom. This specimen was charged into a 10-mL syringe
manufactured by JMS and then pressurized so as to be compressed to
a volume of 7 mL.
Comparative Example 2
[0046] A plurality of nonwoven cloths made of polyethylene
terephthalate having an average fiber diameter of 6.5 .mu.m (pile
density 40 g/m.sup.2), each cloth being punched out in a diameter
of 15 mm, were stacked, and 1.0 g specimen was weighed out
therefrom. This specimen was charged into a 10-mL syringe
manufactured by JMS and then pressurized so as to be compressed to
a volume of 4 mL.
Comparative Example 3
[0047] A plurality of nonwoven cloths made of polypropylene having
an average fiber diameter of 3.5 .mu.m (trade name: Eltasguard
(manufactured by Asahi Kasei Corp.), pile density 17 g/m.sup.2),
each cloth being punched out in a diameter of 15 mm, were stacked,
and 1.0 g specimen was weighed out therefrom. This specimen was
charged into a 10-mL syringe manufactured by JMS and then
pressurized so as to be compressed to a volume of 2 mL.
Experimental Example 1
[0048] Human plasma containing fibrinogen at a concentration of 100
mg/dL was injected into the nonwoven cloth in the syringe of the
filter device for removing fibrinogen obtained in each of Examples
1 to 6 and Comparative Examples 1 to 3, and then filtered by
pressurization with a piston. The proportion of plasma which could
be recovered after filtration and the amount of remaining
fibrinogen were determined by a thrombin time method. The surface
area of the filter of the filter device for removing fibrinogen
obtained in each of Examples 1 to 6 and Comparative Examples 1 to 3
was calculated according to the formula (1) above, and the porosity
was calculated according to the formula (2) above. The results are
shown in Table 1. TABLE-US-00001 TABLE 1 Amount of Surface
Remaining Plasma Area Porosity Fibrinogen Recovery Material
(m.sup.2/g) (%) (mg/dL) (%) Ex. 1 Polyethylene 1.61 83.9 10 or Less
55 Terephthalate Ex. 2 Polyethylene 1.61 77.4 10 or Less 63
Terephthalate Ex. 3 Polyethylene 1.61 69.8 10 or Less 68
Terephthalate Ex. 4 Polyethylene 0.83 83.9 10 or Less 51
Terephthalate Ex. 5 Acryl/Polyester 0.83 83.9 10 or Less 42 Ex. 6
Acryl/Rayon 0.83 83.9 10 or Less 40 Comp. Polyethylene 1.61 89.7 10
or Less 20 Ex. 1 Terephthalate Comp. Polyethylene 0.45 83.9 83 45
Ex. 2 Terephthalate Comp. Polypropylene 0.83 83.9 92 67 Ex. 3
Experimental Example 2
[0049] 1.0 g nonwoven cloth used in each of Examples 1 to 6 and
Comparative Examples 1 to 3 was weighed out and dipped in human
plasma containing fibrinogen at a concentration of 235 mg/dL, and
then the nonwoven cloth only was removed, and the concentration of
fibrinogen in the remaining plasma was measured in the same manner
as in Experimental Example 1, to determine the amount of fibrinogen
adsorbed per g of the nonwoven cloth. The results are shown in
Table 2. TABLE-US-00002 TABLE 2 Amount of Adsorbed Fibrinogen
(mg/g) Ex. 1 2.70 Ex. 2 3.04 Ex. 3 3.30 Ex. 4 1.90 Ex. 5 1.68 Ex. 6
1.50 Comp. Ex. 1 2.40 Comp. Ex. 2 0.72 Comp. Ex. 3 0.50
[0050] From the results in Experiments 1 and 2, it was revealed
that when the filter having a surface area of 0.5 m.sup.2/g or
larger and a porosity of 85% or lower was used, fibrinogen was
removed to the measurement limit or lower upon passage of 100 mg/mL
plasma. When the surface area was lower than 0.5 m.sup.2/g
(Comparative Example 2), fibrinogen could not be completely
removed, and when the porosity was 85% or larger (Comparative
Example 1), the recovery of plasma was as very low as 20%. The
amount of fibrinogen adsorbed was low depending on the material,
and in Comparative Example 3 using polypropylene, fibrinogen could
not be completely removed.
[0051] As shown in Table 3, there was no or less influence, on
measurements, of the treatment for removing fibrinogen by the
filter device for removing fibrinogen obtained in each of Examples
1, 4 and 5. TABLE-US-00003 TABLE 3 Control Example Example Example
Unit (Plasma) 1 4 5 Total Protein g/dl 5.5 5.4 5.4 5.4 (TP) A/G 1.6
1.7 1.8 1.7 Albumin g/dl 3.4 3.4 3.5 3.4 Total mg/dl 0.1 0.1 0.1
0.1 Bilirubin (T-bilirubin) Direct mg/dl 0.0 0.0 0.0 0.0 Bilirubin
(D-bilirubin) GOT IU/I 17 18 17 17 GPT IU/I 7 7 7 7 ALP IU/I 233
235 231 232 LDH IU/I 153 148 150 150 Choline IU/I 4285 4303 4280
4300 Esterase (ChE) .gamma.-GTP IU/I 48 47 47 46 LAP IU/I 46 45 46
45 CPK IU/I 61 64 65 65 Amylase IU/I 50 49 50 51 (Blood) Total
Lipid mg/dl 455 455 440 466 LDL- mg/dl 117 113 113 114 Cholesterol
(Direct) .beta.- mg/dl 369 363 368 370 Lipoprotein Free Fatty mEq/l
0.47 0.48 0.47 0.47 Acid (NEFA) Phospholipid mg/dl 185 177 182 181
(PL) Uric Acid (UA) mg/dl 5.2 5.2 5.2 5.2 Urea Nitrogen mg/dl 7.2
7.0 7.3 7.3 (BUN) Creatine (CRE) mg/dl 0.79 0.77 0.77 0.77 Na mEq/l
171 172 171 171 Cl mEq/l 88 88 88 88 K mEq/l 4.1 4.1 4.1 4.1 Ca
mg/dl 7.9 7.8 7.8 7.7 Inorganic mg/dl 1.5 1.5 1.5 1.5 Phosphorus
(IP) Mg mg/dl 1.4 1.4 1.4 1.4 Serum Iron mg/dl 54 56 54 56 (Fe)
TIBC .mu.g/dl 226 226 228 228 UIBC .mu.g/dl 172 170 174 172
INDUSTRIAL APPLICABILITY
[0052] According to the present invention, fibrinogen only can be
removed by adsorption without adsorbing and removing proteins other
than fibrinogen contained in plasma, and thus examination results
of samples after treatment are not affected, and the problem of
frequent precipitation of fibrin in serum from a patient given
heparin can be completely solved.
* * * * *